Phase 2's a crowd

摘要

The pipeline at Metabolic Pharmaceuticals is fit to burst. At time of print, Metabolic's obesity drug is in the final chapter of Phase 2 trials; their treatment for neuropathic pain is well advanced into Phase 2 planning; and since their obesity drug also works for osteoporosis, it has rocketed into eligibility for probable direct entry to Phase 2 osteoporosis studies. First off the ranks will be obesity drug AOD9604. With over one billion obese people in the world, and market forecasts topping 30billion US dollars, CEO Roland Scollay says Metabolic is on a winner. "The problem of overweight affects somewhere between 50 and 70 percent of the adult population." And what if we all went on a massive health kick? "Even if the obesity problem halved and the overweight population went from 70 percent to 35 percent, that's still a huge, huge market."